References
- Wu TD, Brigham EP, McCormack MC. Asthma in the primary care setting. Med Clin North Am. 2019;103:435–452.
- Murillo JC, Dimov V, Gonzalez-Estrada A. An evaluation of fevipiprant for the treatment of asthma: a promising new therapy? Expert Opin Pharmacother. 2018;19:2087–2093.
- Del Rio P R, Liu AH, Borres MP, et al. Asthma and allergy: unravelling a tangled relationship with a focus on new biomarkers and treatment. Int J Mol Sci. 2022;23:3881.
- Pearson D, Weiss HM, Jin Y, et al. Absorption, distribution, metabolism, and excretion of the oral prostaglandin D2 receptor 2 antagonist fevipiprant (QAW039) in healthy volunteers and in vitro. Drug Metab Dispos. 2017;45:817–825.
- Rehman A, Amin F, Sadeeqa S. Prevalence of asthma and its management: a review. J Pak Med Assoc. 2018;68:1823–1827.
- Ahmad A. Pharmacological strategies and recent advancement in nano-drug delivery for targeting asthma. Life (Basel). 2022;12:596.
- Chowdhury NU, Guntur VP, Newcomb DC, et al. Sex and gender in asthma. Eur Respir Rev. 2021;30:210067.
- Kwah JH, Peters AT. Asthma in adults: Principles of treatment. Allergy Asthma Proc. 2019;40:396–402.
- White C, Wright A, Brightling C. Fevipiprant in the treatment of asthma. Expert Opin Investig Drugs. 2018;27:199–207.
- Jat KR, Gupta A. Recent advances in long-term management of asthma. Indian J Pediatr. 2022;89:378–386.
- Mathis BJ, Kusumoto M, Zaboronok A, et al. Packaging and delivery of asthma therapeutics. Pharmaceutics. 2021;14:92.
- Castillo JR, Peters SP, Busse WW. Asthma exacerbations: Pathogenesis, prevention, and treatment. J Allergy Clin Immunol Pract. 2017;5:918–927.
- Bateman ED, Guerreros AG, Brockhaus F, et al. Fevipiprant, an oral prostaglandin DP(2) receptor (CRTh2) antagonist, in allergic asthma uncontrolled on low-dose inhaled corticosteroids. Eur Respir J. 2017;50:1700670.
- Farne H, Glanville N, Johnson N, et al. Effect of CRTH2 antagonism on the response to experimental rhinovirus infection in asthma: a pilot randomised controlled trial. Thorax. 2021;217429.
- Lee HY, Lee HY, Hur J, et al. Blockade of thymic stromal lymphopoietin and CRTH2 attenuates airway inflammation in a murine model of allergic asthma. Korean J Intern Med. 2020;35:619–629.
- Santini G, Mores N, Malerba M, et al. Investigational prostaglandin D2 receptor antagonists for airway inflammation. Expert Opin Investig Drugs. 2016;25:639–652.
- Erpenbeck VJ, Vets E, Gheyle L, et al. Pharmacokinetics, safety, and tolerability of fevipiprant (QAW039), a novel CRTH2 receptor antagonist: results from 2 randomized, phase 1, placebo-controlled studies in healthy volunteers. Clin Pharmacol Drug Dev. 2016;5:306–313.
- Norman P. Update on the status of DP2 receptor antagonists; from proof of concept through clinical failures to promising new drugs. Expert Opin Investig Drugs. 2014;23:55–66.
- Santus P, Radovanovic D. Prostaglandin D2 receptor antagonists in early development as potential therapeutic options for asthma. Expert Opin Investig Drugs. 2016;25:1083–1092.
- Erpenbeck VJ, Popov TA, Miller D, et al. The oral CRTh2 antagonist QAW039 (fevipiprant): a phase II study in uncontrolled allergic asthma. Pulm Pharmacol Ther. 2016;39:54–63.
- Bain G, King CD, Brittain J, et al. Pharmacodynamics, pharmacokinetics, and safety of AM211: a novel and potent antagonist of the prostaglandin D2 receptor type 2. J Clin Pharmacol. 2012;52:1482–1493.
- Sidharta PN, Diamant Z, Dingemanse J. Single- and multiple-dose tolerability and pharmacokinetics of the CRTH2 antagonist setipiprant in healthy male subjects. Fundam Clin Pharmacol. 2014;28:690–699.
- Wang YH, Trucksis M, McElwee JJ, et al. UGT2B17 genetic polymorphisms dramatically affect the pharmacokinetics of MK-7246 in healthy subjects in a first-in-human study. Clin Pharmacol Ther. 2012;92:96–102.